文献速递免疫规划

接受免疫抑制药物治疗者接种HepB-CpG疫苗

Vaccination with HepB-CpG vaccine in individuals undergoing immune suppressive drug therapy.
PubMed 文献 · Vaccine · 2023-06-21

本研究在10名接受生物制剂或抗排斥治疗的免疫抑制患者中接种经FDA批准的含免疫佐剂乙型肝炎疫苗HepB-CpG,于第0周和第4周各接种一剂,若第12周时抗-HBs仍低于10 mIU/mL则接种第三剂。结果显示70%的参与者在第24周产生具有血清保护作用的抗-HBs,接受生物制剂者抗体应答更迅速,而移植受者通常需要第三剂。

要点

  • 10名接受生物制剂或抗排斥治疗者接种HepB-CpG,第24周70%产生血清保护性抗-HBs。
  • 接受生物制剂者抗体应答更迅速,抗-HBs超过100 mIU/mL者较多。
  • 抗排斥治疗的6名移植受者中仅2人第24周抗-HBs超过100 mIU/mL,第三剂可改善抗体应答。

核心结论

  • 70%的参与者在接种HepB-CpG后产生具有血清保护作用的抗-HBs。
  • 接受生物制剂者抗体应答更迅速,而移植受者接种第三剂可改善抗体应答。

研究设计与样本

  • 在10名接受生物制剂或抗排斥治疗的医学免疫抑制个体中测试经FDA批准的含免疫佐剂乙型肝炎疫苗(HEPLISAV-B®或HepB-CpG)。
  • 受试者在第0周和第4周各接种一剂,若第12周时抗-HBs仍低于10 mIU/mL则接种第三剂。

主要发现

  • 70%的参与者在第24周产生具有血清保护作用的抗-HBs。
  • 接受生物制剂者抗体应答更迅速,而移植受者通常需要第三剂。
  • 第24周时,接受生物制剂者中多数抗-HBs水平超过100 mIU/mL,而接受抗排斥治疗的6人中仅2人超过100 mIU/mL。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunosuppressed patients are a targeted group for HBV vaccination but suboptimal antibody responses occur when traditional recombinant vaccines are used. METHODS: We tested an FDA approved immune adjuvanted HBV vaccine (HEPLISAV--B® or HepB-CpG) in medically immune suppressed individuals. HepB-CpG was given to 10 patients taking biologic agents or anti-rejection therapy. Each received vaccine at time 0 and week 4 with a third dose at week 12 if anti-HBs remained less than 10 mIU/mL. RESULTS: Seroprotective anti-HBs developed in 70 % of participants by week 24. Those taking biologic agents responded more rapidly and a third dose was generally needed in those transplanted. By week 24, most taking biologics but only 2 of 6 on anti-rejection treatment had antibody levels exceeding 100 mIU/mL. CONCLUSIONS: Seroprotective anti-HBs developed in 70 % with HepB-CpG. Antibody responses were more rapid in those taking biologic agents but a third dose improved antibody responses in transplanted participants.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Perrillo R, Garrido LF, Ma TW, et al. Vaccination with HepB-CpG vaccine in individuals undergoing immune suppressive drug therapy. Vaccine. 2023. PMID: 37353450. doi:10.1016/j.vaccine.2023.06.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。